Saad Usmani, MD, presents a case of a 75-year-old woman with multiple myeloma and describes the patient’s current prognosis.
A 75-Year-Old Woman With Multiple Myeloma
Saad Usmani, MD, discusses what first-line options are available for patients with multiple myeloma while highlighting the difficulties in defining high-risk characteristics associated with multiple myeloma.
Saad Usmani, MD, analyzes the efficacy and safety data results from the phase 3 MAIA study.
The MAIA & PEGASUS Trial and Managing Patients Receiving DRd
Saad Usmani, MD, reflects on the impact the coronavirus pandemic has had on his practice and the treatment of patients with multiple myeloma overall.
Saad Usmani, MD, speculates on the current progress in treating multiple myeloma, while providing a glimpse into the future of cutting-edge treatments.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
